EU to buy additional 300 million Pfizer/BioNTech vaccine doses

Ritratt - Kummissjoni Ewropea 2020

Tista' taqra bil- Malti.

The EU reached a deal with Pfizer and BioNTech to purchase and additional 300 million doses of their COVID-19 vaccine. The head of the European Commission Ursula Von Der Leyen announced this on Friday. Through this agreement, the EU is committing itself to buy nearly half of the firms’ global output for 2021.

Pfizer had announced that it can produce globally up to 1.3 billion doses this year. The new agreement with the EU comes on top of another order for 300 million doses that the bloc agreed with Pfizer and its German partner BioNTech in November. 

Von Der Leyen said “We now have agreed with BioNTech and Pfizer to extend this contract. With the new agreement we could purchase a total of up to an additional 300 million doses of the BioNTech vaccine.”

EU governments will be in a position to order new doses from April.

The EU has acquired a broad portfolio of vaccines with different technologies. It has secured up to 2.3 billion doses from the most promising vaccine candidates.
In addition to the BioNTech-Pfizer vaccine, a second vaccine, produced by Moderna, was authorised on Wednesday. Other vaccines are expected to be approved soon.
This vaccine portfolio would enable the EU not only to cover the needs of its whole population, but also to supply vaccines to neighbouring countries.